Compare · ALEC vs ARGX
ALEC vs ARGX
Side-by-side comparison of Alector Inc. (ALEC) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALEC and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 304.7x ALEC ($181.5M).
- Over the past year, ALEC is up 13.2% and ARGX is up 52.8% - ARGX leads by 39.6 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 4 for ALEC).
- Both have 25 recent analyst ratings on file.
- Company
- Alector Inc.
- argenx SE
- Price
- $1.63-9.70%
- $891.80+5.79%
- Market cap
- $181.5M
- $55.32B
- 1M return
- -36.45%
- +10.56%
- 1Y return
- +13.19%
- +52.81%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2017
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 25
Alector Inc.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies. The company was founded in 2013 and is headquartered in South San Francisco, California.
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ALEC
- Director Scheller Richard H was granted 10,833 shares, increasing direct ownership by 11% to 106,199 units (SEC Form 4)
- Chief Executive Officer Rosenthal Arnon sold $172,191 worth of shares (87,216 units at $1.97), decreasing direct ownership by 4% to 2,367,206 units (SEC Form 4) to cover withholding tax
- Principal Accounting Officer Wong-Sarad Grace sold $17,813 worth of shares (9,184 units at $1.94) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,461 units (SEC Form 4) to satisfy tax liability
- CFO & Chief Business Officer Berkley Neil Lindsay sold $38,221 worth of shares (19,360 units at $1.97), decreasing direct ownership by 5% to 379,900 units (SEC Form 4) to cover taxes
- Amendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.
- SEC Form 8-K filed by Alector Inc.
- SEC Form 424B5 filed by Alector Inc.
- SEC Form 10-Q filed by Alector Inc.
- Alector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference